Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carolin C Hack

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
Breast Cancer Research and Treatment|March 13, 2013
Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasisChristian R Loehberg, Katrin Almstedt, Sebastian M Jud, et al.
Archives of Gynecology and Obstetrics|June 10, 2017
Gynecologic oncologists' attitudes and practices relating to integrative medicine: results of a nationwide AGO surveyEvelyn Klein, Matthias W Beckmann, Werner Bader, et al.
Archives of Gynecology and Obstetrics|March 24, 2017
Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study networkCarlo Fremd, Carolin C Hack, Andreas Schneeweiss, et al.
Breast Care (Basel, Switzerland)|June 29, 2018
TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating LymphocytesFranziska Würfel, Ramona Erber, Hanna Huebner, et al.
Journal of the National Cancer Institute|March 7, 2015
The contributions of breast density and common genetic variation to breast cancer riskCeline M Vachon, V Shane Pankratz, Christopher G Scott, et al.
Geburtshilfe Und Frauenheilkunde|November 5, 2019
Diagnosis, Therapy and Follow-up of Vaginal Cancer and Its Precursors. Guideline of the DGGG and the DKG (S2k-Level, AWMF Registry No. 032/042, October 2018)Hans-Georg Schnürch, Sven Ackermann, Celine D Alt-Radtke, et al.
BMC Cancer|October 16, 2024
The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtypePhilipp Ziegler, Andreas D Hartkopf, Markus Wallwiener, et al.
European Journal of Cancer (Oxford, England : 1990)|August 8, 2025
Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancerLaura L Michel, Philipp Ziegler, Philipp Kreis, et al.
Geburtshilfe Und Frauenheilkunde|May 31, 2024
CDK4/6 Inhibition - Therapy Sequences and the Quest to Find the Best Biomarkers - an Overview of Current ProgramsAndreas Schneeweiss, Sara Y Brucker, Hanna Huebner, et al.
European Journal of Cancer (Oxford, England : 1990)|July 26, 2024
Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozolePeter A Fasching, Carolin C Hack, Naiba Nabieva, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
Breast Cancer Research and Treatment|March 13, 2013
Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasisChristian R Loehberg, Katrin Almstedt, Sebastian M Jud, et al.
Archives of Gynecology and Obstetrics|June 10, 2017
Gynecologic oncologists' attitudes and practices relating to integrative medicine: results of a nationwide AGO surveyEvelyn Klein, Matthias W Beckmann, Werner Bader, et al.
Archives of Gynecology and Obstetrics|March 24, 2017
Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study networkCarlo Fremd, Carolin C Hack, Andreas Schneeweiss, et al.
Breast Care (Basel, Switzerland)|June 29, 2018
TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating LymphocytesFranziska Würfel, Ramona Erber, Hanna Huebner, et al.
Journal of the National Cancer Institute|March 7, 2015
The contributions of breast density and common genetic variation to breast cancer riskCeline M Vachon, V Shane Pankratz, Christopher G Scott, et al.
Geburtshilfe Und Frauenheilkunde|November 5, 2019
Diagnosis, Therapy and Follow-up of Vaginal Cancer and Its Precursors. Guideline of the DGGG and the DKG (S2k-Level, AWMF Registry No. 032/042, October 2018)Hans-Georg Schnürch, Sven Ackermann, Celine D Alt-Radtke, et al.
BMC Cancer|October 16, 2024
The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtypePhilipp Ziegler, Andreas D Hartkopf, Markus Wallwiener, et al.
European Journal of Cancer (Oxford, England : 1990)|August 8, 2025
Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancerLaura L Michel, Philipp Ziegler, Philipp Kreis, et al.
Geburtshilfe Und Frauenheilkunde|May 31, 2024
CDK4/6 Inhibition - Therapy Sequences and the Quest to Find the Best Biomarkers - an Overview of Current ProgramsAndreas Schneeweiss, Sara Y Brucker, Hanna Huebner, et al.
European Journal of Cancer (Oxford, England : 1990)|July 26, 2024
Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozolePeter A Fasching, Carolin C Hack, Naiba Nabieva, et al.
Pageof 10